OnkoSight Advanced^TM Rapid AML Panel

Acute Myeloid Leukemia (AML) is a life-threatening hematological disease and represents the most common acute leukemia in adults. AML is typically characterized by multiple somatically acquired mutations that affect all genes of different functional categories.

The OnkoSight Advanced^TM Rapid AML NGS panel represents an exquisitely sensitive, technically robust solution for the rapid detection of genomic alterations defined by National Cancer Comprehensive Network (NCCN) guidelines as clinically relevant to AML, including large FLT3 internal tandem duplication mutations (ITD) and point mutations or deletion in the tyrosine kinase domain (TKD), IDH1/2 mutations, CEBPA (biallelic), and alteration in NPM1, among others.

Advantages of GenPath^® for NGS Evaluation of AML:

Industry-leading Turnaround Time

NGS test results for AML are available in as fast as 3 days* – for timely initiation of medical management.

High Clinical Utility

Targeted, tumor-specific NGS panel includes all gene mutations with clear therapeutic, diagnostic, or prognostic significance. NGS panel content is aligned with the latest NCCN and European LeukemiaNet (ELN) guideline recommendations.

Customized Report

• Reviewed and reported by board-certified molecular pathologists or clinical molecular geneticists.
• Relevant clinical history and ancillary findings from morphology, flow cytometry, etc., are incorporated in the NGS case analysis – a process improvement advantage in using a single-source laboratory for a comprehensive cancer patient workup.
• Detected variants are reported following AMP/ASCO/CAP recommendations.

*Reporting times are typical and begin once the specimen is received at the laboratory, but could be extended in situations outside GenPath’s reasonable control.